Idera Pharmaceuticals to Provide ILLUMINATE-204 Clinical Data Update on Friday, December 14, 2018
December 12 2018 - 4:01PM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage
biopharmaceutical company focused on the development and ultimate
commercialization of drug candidates for both oncology and rare
disease indications characterized by small, well-defined patient
populations with serious unmet needs, today announced that it plans
to release an update on clinical data from the ongoing Phase 2
trial of the combination of intratumoral tilsotolimod and
ipilimumab for unresectable or metastatic melanoma following
failure of anti-PD-1 inhibitor treatment prior to the opening of
the U.S. financial markets on Friday, December 14, 2018.
The company will host a conference call and live webcast,
Friday, December 14 at 10:00 A.M. EST to review the data being
presented along with a questions and answers session.
Investor Webcast DetailsTo participate in the
conference call, please dial (844) 882-7837 (domestic) and (574)
990-9824 (international). The webcast can be accessed live or
in archived form in the “Investors” section of the company’s
website at www.iderapharma.com. The company will be posting a
slide presentation to the Idera corporate website in the
“Investors” section which will be referenced during the conference
call.
Live audio webcast of Idera’s presentations will be accessible
in the Investors and Media section of Idera’s website at
http://www.iderapharma.com. Archived versions will also be
available on the Company’s website after the event for 90
days.
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and the
Company’s vast experience in developing proprietary immunology
platforms, Idera’s lead development program is focused on priming
the immune system to play a more powerful role in fighting cancer,
ultimately increasing the number of people who can benefit from
immunotherapy. Idera also continues to focus on the acquisition,
development and ultimate commercialization of drug candidates for
both oncology and rare disease indications characterized by small,
well-defined patient populations with serious unmet needs. To learn
more about Idera, visit www.iderapharma.com.
Forward Looking Statements This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. All statements,
other than statements of historical fact, included or incorporated
in this press release, including statements regarding the Company's
strategy, future operations, collaborations, intellectual property,
cash resources, financial position, future revenues, projected
costs, prospects, clinical trials, plans, and objectives of
management, are forward-looking statements. The words "believes,"
"anticipates," "estimates," "plans," "expects," "intends," "may,"
"could," "should," "potential," "likely," "projects," "continue,"
"will," and "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Idera
cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company's
forward-looking statements. There are a number of important factors
that could cause Idera's actual results to differ materially from
those indicated or implied by its forward-looking statements.
Factors that may cause such a difference include: whether the
Company’s cash resources will be sufficient to fund the Company’s
continuing operations and the further development of the Company’s
programs for the period anticipated; whether interim results from a
clinical trial, such as the preliminary results reported in this
release, will be predictive of the final results of the trial;
whether results obtained in preclinical studies and clinical trials
such as the results described in this release will be indicative of
the results that will be generated in future clinical trials,
including in clinical trials in different disease indications;
whether products based on Idera's technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors as are set forth under
the caption "Risk factors" in the Company’s Annual Report filed on
Form 10-K for the period ended December 31, 2017 and the Company’s
Quarterly Report filed on Form 10-Q for the period ended September
30, 2018. Although Idera may elect to do so at some point in the
future, the Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Idera Pharmaceuticals contact:Robert A. Doody, Jr.VP, Investor
Relations & CommunicationsPhone (484)
484-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2024 to Jun 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jun 2023 to Jun 2024